Omeros expands board to nine, appoints Joseph Schocken

What happened

On August 12, 2026, the board of directors of Omeros Corporation, a Seattle-based biopharmaceutical company, increased the number of its directors from eight to nine and appointed Joseph Schocken as a director, effective immediately, according to an 8-K filed with the SEC on August 13, 2026.

Mr. Schocken, 79, is a private investor and founder of Tranceka Capital, LLC. He founded Seattle-based investment bank Broadmark Capital LLC in 1987 and co-founded the entities that became Broadmark Realty Capital, Inc., where he served as CEO and later as chairman. He currently serves as chairman of Taqtile, Inc., a digital work assistance platform.

The board also appointed Mr. Schocken to its Audit Committee. His initial term expires at the 2027 annual meeting of shareholders or earlier upon resignation or removal.

Pursuant to Omeros's non-employee director compensation policy, Mr. Schocken received a stock option to purchase 30,000 shares of common stock on the date of his appointment.

Context

Omeros Corporation focuses on developing and commercializing therapies for inflammatory and complement-mediated diseases and central nervous system disorders.

The filing states that Mr. Schocken is not party to any understanding or arrangement in connection with his appointment and has no material interest in any existing or proposed transaction requiring disclosure.

Shares closed at $17.17 on August 13, down 1.04% from the prior close of $17.35, based on price data provided.

What this means

An 8-K is a current report that public companies must file with the SEC to announce major events, including changes to directors or officers. Item 5.02 covers departures, elections, and appointments of directors and certain officers.

This filing discloses that the board expanded and immediately appointed Mr. Schocken, which is a routine but notable governance event. The option grant is a standard part of director compensation, intended to align the director's interests with shareholders.

Normally, a newly appointed director's term runs until the next annual meeting, and the board may consider re-election at that time. The appointment to the Audit Committee also adds a new member to that oversight body.